Endocrine Abstracts

BackgroundThyrotropin Stimulating Hormone Suppression Therapy (TSHST) in Differentiated Thyroid cancer (DTC) patients can result in reduced bone mineral density (BMD) which is a potential serious problem [1]. Studies on the effects of TSHST on BMD have demonstrated conflicting results [2–5]. There is insufficient guidance regarding the degree and duration of TSHST in the context of skeletal effects despite multiple existing guidelines.<p class="...